Overview
Wholesale Trade

Alfresa Holdings Corporation

Alfresa Holdings Corporation is a holding company operating one of Japan's largest pharmaceutical distribution groups, with Alfresa Corporation as its core subsidiary engaged in the wholesale distribution of prescription pharmaceuticals, diagnostic reagents, and medical devices/materials to hospitals, clinics, and pharmacies nationwide. The Group also operates OTC pharmaceutical wholesale through Alfresa Healthcare, pharmaceutical and diagnostic reagent manufacturing through Alfresa Pharma, and dispensing pharmacy management through Apocreate. Additional businesses include fine chemical manufacturing, CRO/PMS services, regenerative medicine materials, and healthcare IT systems.

Market Cap
¥422B
US$2.69B
EV
¥167B
US$1.07B
Stock¥2,406.5▲+1.45%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
3.3
x
LTM EV/EBIT
4.8
x
LTM PER
10.8
x
LTM PBR
0.9
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-11.7%pt
1001234
Oct 23, 25 – Oct 23, 26StockTOPIX
1Nov 4, 25Silchester International Investors LLP changed stake (11.1%→12.11%)
2Apr 1, 26Activist fund stake acquisition
3Jun 5, 26Silchester International Investors LLP changed stake (12.11%→13.17%)
4Aug 5, 26Q1 FY2027/03 earnings announced
MC → EV Bridge
422BUS$2.69BMarket Cap35.6BUS$227M+ Debt178BUS$1.14B− Cash113BUS$721M− Inv. Sec.0.69BUS$4.41M+ NCI167BUS$1.07BEV
AI Briefing
Top-tier pharma wholesale holding co: nationwide distribution, manufacturing (API/diagnostics) and dispensing pharmacies via 20+ subsidiaries. FY26/3 revenue ¥3,104B but OP margin thin at 1.2% (¥36.2B), slipping from FY25/3's ¥38.1B despite top-line growth. Large-cap scale (¥412B mkt cap) with net cash position (¥178B cash vs ¥35.6B debt) — low-margin, high-volume distribution economics typical of the sector.
Performance & Balance
Revenue 5Y (¥B)
2,586US$16.5B'22/32,696US$17.2B'23/32,859US$18.2B'24/32,961US$18.9B'25/33,104US$19.8B'26/3
EBITDA 5Y (¥B)
41.3US$263M'22/343.0US$274M'23/351.5US$328M'24/352.5US$335M'25/350.8US$324M'26/3
Net Income 5Y (¥B)
32.2US$205M'22/325.8US$164M'23/329.6US$189M'24/327.4US$175M'25/341.7US$266M'26/3
Capital Structure
93%
EquityD/E 0.07xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
268US$1.71B5.04US$32.1M'22/3252US$1.61B3.86US$24.6M'23/3319US$2.04B34.9US$223M'24/3292US$1.86B35.5US$227M'25/3299US$1.91B35.6US$227M'26/3
Shareholders
Top 10 hold 40.4%
1
The Master Trust Bank of Japan, Ltd. (Trust Account)
13.71%
2
NORTHERN TRUST CO.(AVFC)RE SILCHESTER INTERNATIONALINVESTORS INTERNATIONALVALUE EQUITY TRUST (Standing Proxy: The Hongkong and Shanghai Banking Corporation Limited, Tokyo Branch)
5.38%
3
Custody Bank of Japan, Ltd. (Trust Account)
4.58%
4
NORTHERN TRUST CO.(AVFC) RE U.S. TAX EXEMPTED PENSION FUNDS (Standing Proxy: The Hongkong and Shanghai Banking Corporation Limited, Tokyo Branch)
3.21%
5
STATE STREET BANK AND TRUST COMPANY505051 (Standing Proxy: Mizuho Bank, Ltd.)
2.90%
6
Alfresa Holdings Corporation Employee Stock Ownership Association
2.85%
7
NORTHERN TRUST CO.(AVFC)RE NON TREATY CLIENTS ACCOUNT (Standing Proxy: The Hongkong and Shanghai Banking Corporation Limited, Tokyo Branch)
2.27%
8
Mizuho Trust & Banking Co., Ltd. (Retirement Benefit Trust, DAIICHI SANKYO COMPANY,LIMITED Account; Re-trustee: Custody Bank of Japan, Ltd.)
1.95%
9
NORTHERN TRUST CO.(AVFC) RE IEDU UCITS CLIENTS NON LENDING 15PCT TREATY ACCOUNT (Standing Proxy: The Hongkong and Shanghai Banking Corporation Limited, Tokyo Branch)
1.86%
10
Yusuke FUKUGAMI
1.65%
Management
12 officers
Ryuji ARAKAWA
Representative Director, President
Apr 1987 Joined Yamanouchi Pharmaceutical Co., Ltd. (currently Astellas Pharma Inc.) Apr 1999 Joined Chuyaku Co., Ltd. (currently Alfresa Corporation) Jun 2000 Director, Chuyaku Co., Ltd. Jun 2005 Managing Director, CS Pharmaceutical Co., Ltd. (currently Alfresa Corporation) Jun 2007 Senior Managing Director, CS Pharmaceutical Co., Ltd.; Director of the Company Jun 2008 Director and Senior Managing Executive Officer, CS Pharmaceutical Co., Ltd. Apr 2009 Representative Director, President, CS Pharmaceutical Co., Ltd. Jun 2016 Director of the Company Oct 2016 Managing Executive Officer, in charge of Business Development, the Company Apr 2020 Director and Senior Managing Executive Officer, in charge of Corporate Communications, Business Development and Overseas Business, the Company Jun 2020 Representative Director, President of the Company (current) Apr 2025 Representative Director, Chairman, Alfresa Corporation (current)
1963-03-05
Yusuke FUKUGAMI
Representative Director, Vice President, in charge of Pharmaceutical Wholesale Business and Overseas Business
Apr 2000 Joined Fukugami Co., Ltd. (currently Alfresa Corporation) Apr 2011 General Manager, Distribution Planning Department, Logistics Division, Alfresa Corporation Oct 2012 General Manager, Sales Planning Department, Sales Division, Alfresa Corporation Apr 2014 Executive Officer, General Manager, Sales Planning Department, Sales Division, Alfresa Corporation Apr 2019 Managing Executive Officer, General Manager, Logistics Division, Alfresa Corporation Jun 2019 Director and Managing Executive Officer, General Manager, Logistics Division, Alfresa Corporation Apr 2020 Director and Senior Managing Executive Officer, General Manager, Logistics Division, Alfresa Corporation Jun 2020 Representative Director, President, Alfresa Corporation (current); Director of the Company Apr 2022 Director, Vice President of the Company, in charge of Pharmaceutical Wholesale Business Jun 2023 Representative Director, Vice President of the Company, in charge of Pharmaceutical Wholesale Business and Total Supply Chain Services Apr 2024 Representative Director, Vice President of the Company, in charge of Pharmaceutical Wholesale Business, Total Supply Chain Services and Overseas Business Apr 2025 Representative Director, Vice President of the Company, in charge of Pharmaceutical Wholesale Business and Overseas Business (current)
1976-06-27
Shigeki OHASHI
Director, Managing Executive Officer, in charge of Business Strategy (overseeing Business Planning and Total Supply Chain Service Planning)
Mar 1988 Joined Showa Yakuhin Co., Ltd. (currently Alfresa Pharma Corporation) Oct 2008 General Manager, Tokyo Joto Sales Department, Sales Division, Alfresa Corporation Oct 2016 General Manager, Merchandise Management Department, Logistics Division, Alfresa Corporation Apr 2018 Executive Officer, General Manager, Sales Strategy Department, Pharmaceutical Sales Division, Alfresa Corporation Oct 2019 Executive Officer, Deputy General Manager, Pharmaceutical Sales Division, Alfresa Corporation Apr 2020 Managing Executive Officer, in charge of Group Business, the Company Jun 2022 Director and Managing Executive Officer, in charge of Group Planning, Business Development and Overseas Business, the Company Apr 2024 Director and Managing Executive Officer, General Manager, Group Pharmaceutical Wholesale Business Division, the Company Apr 2025 Director and Managing Executive Officer, in charge of Business Strategy (overseeing Business Planning and Total Supply Chain Service Planning), the Company (current)
1965-01-17
Toshiki TANAKA
Director, Managing Executive Officer, in charge of Corporate (overseeing General Affairs, Financial Planning and Corporate Communications)
Apr 1986 Joined Sanwa Bank, Ltd. (currently MUFG Bank, Ltd.) Oct 2012 General Manager, Syndication Department, The Bank of Tokyo-Mitsubishi UFJ, Ltd. (currently MUFG Bank, Ltd.) Jul 2015 Joined Alfresa Corporation, General Manager, Administration Division Apr 2016 Executive Officer, Deputy General Manager, Administration Division, Alfresa Corporation Apr 2017 Executive Officer, Deputy General Manager, Administration Division, and General Manager, Accounting Department, Alfresa Corporation Apr 2019 Executive Officer, General Manager, Corporate Planning Department, Alfresa Corporation Jun 2020 Director and Managing Executive Officer, General Manager, Logistics Division, Alfresa Corporation Apr 2022 Director, Alfresa Corporation; Managing Executive Officer of the Company, in charge of General Affairs, Human Resources Planning, DX Promotion and Compliance Jun 2022 Director and Managing Executive Officer, in charge of General Affairs, Human Resources Planning, DX Promotion and Compliance, the Company Apr 2024 Director and Managing Executive Officer, in charge of Group Management Strategy, Human Resources Planning, IT, DX Promotion and Regenerative Medicine Business, the Company Apr 2025 Director and Managing Executive Officer, in charge of Corporate (overseeing General Affairs, Financial Planning and Corporate Communications), the Company (current)
1963-06-03
Koichi SHIMADA
Director
Apr 1982 Joined Nihon Shoji Co., Ltd. (currently Alfresa Pharma Corporation) Apr 2008 Executive Officer, General Manager, Product Strategy Department, Alfresa Pharma Corporation Jun 2010 Director, Alfresa Pharma Corporation Apr 2012 Director and Managing Executive Officer, Alfresa Pharma Corporation Apr 2014 Director and Senior Managing Executive Officer, Alfresa Pharma Corporation Apr 2016 Director and Executive Vice President, Alfresa Pharma Corporation May 2016 Director, Alfresa Fine Chemical Co., Ltd. Apr 2017 Representative Director, President and Executive Officer, Alfresa Pharma Corporation May 2017 Chairman, Director, Alfresa Fine Chemical Co., Ltd. Jun 2018 Director of the Company (current) Apr 2025 Representative Director, Chairman and Executive Officer, Alfresa Pharma Corporation (current)
1958-10-15
Manabu KINOSHITA
Director
Apr 1978 Joined NEC Corporation Apr 2008 Executive Officer, NEC Corporation Apr 2010 Executive Officer, Managing Director, NEC Corporation Jun 2010 Director, Executive Officer, Managing Director, NEC Corporation Jun 2011 Executive Officer, Managing Director, NEC Corporation Apr 2016 Executive Officer, Senior Vice President, NEC Corporation Apr 2018 Senior Officer, NEC Corporation Jun 2020 Director of the Company (current); Outside Director, Sumitomo Metal Mining Co., Ltd. (current) Jun 2023 Outside Director, Meidensha Corporation (current)
1954-05-17
Yoshie TAKEUCHI
Director
Apr 1978 Joined Lion Oil & Fat Co., Ltd. (currently Lion Corporation) Jul 2001 Joined Dentsu EYE Inc. Apr 2002 Visiting Professor, Graduate School of Social Sciences, Hosei University Apr 2003 Professor, Faculty of Business Administration, Hosei University Apr 2012 Dean, Graduate School of Business Administration, Hosei University Apr 2014 Dean, Faculty of Business Administration, Hosei University Apr 2016 Director, Career Center, Hosei University Jun 2020 Director of the Company (current) Apr 2025 Professor Emerita, Hosei University
1955-01-22
Kimiko KUNIMASA
Director
Mar 1982 Joined Fukutake Shoten Co., Ltd. (currently Benesse Holdings, Inc.) Jun 2000 Director, Benesse Corporation Jan 2002 President, Benesse Care Co., Ltd. (currently Benesse Style Care Co., Ltd.) Dec 2003 Director, Benesse Style Care Co., Ltd. Jun 2008 General Manager, Human Resources and General Affairs Division, Benesse Corporation Oct 2010 Chief Human Resources Officer, Benesse Holdings, Inc. Apr 2012 Director, Benesse Corporation Jun 2013 Deputy President, Director, Benesse Style Care Co., Ltd. Jun 2022 Director of the Company (current) Jun 2023 Outside Director, Mitsubishi Shokuhin Co., Ltd.
1960-01-30
Yuji UEDA
Director (Audit and Supervisory Committee Member)
Apr 1983 Joined Daiwa Yakuhin Co., Ltd. (currently Shikoku Alfresa Corporation) Apr 2003 Executive Officer, Daiwa Yakuhin Co., Ltd. Oct 2005 Executive Officer, Shikoku Alfresa Corporation Apr 2007 Senior Manager, Group Planning Department, the Company Apr 2011 General Manager, Business Review Department, and Senior Manager, Group Planning Department, the Company Jul 2012 General Manager, Group Planning Department, the Company Apr 2013 General Manager, Internal Audit Department, the Company Jul 2014 General Manager, Business Review Department, and General Manager, General Affairs Department, the Company Apr 2015 Executive Officer, General Manager, Business Review Department and General Affairs Department, the Company Oct 2016 Executive Officer, General Manager, General Affairs Department, the Company Apr 2017 Executive Officer, General Manager, Internal Control and Legal Affairs Department, the Company Oct 2018 Executive Officer, General Manager, Internal Audit Department, the Company Jun 2022 Full-time Audit & Supervisory Board Member, the Company Jun 2025 Director (Audit and Supervisory Committee Member) of the Company (current)
1961-04-01
Taku ITO
Director (Audit and Supervisory Committee Member)
Apr 1988 Registered as attorney-at-law (Daini Tokyo Bar Association) Oct 2002 Opened Shin-Yotsuya Law Office Apr 2005 Vice President, Daini Tokyo Bar Association Apr 2008 Deputy Secretary General, Japan Federation of Bar Associations Apr 2011 Director, Public Relations Office, Daini Tokyo Bar Association Apr 2012 Special Advisor to the Secretary General, Japan Federation of Bar Associations Apr 2016 Managing Director, Japan Federation of Bar Associations Apr 2017 President, Daini Tokyo Bar Association; Vice President, Japan Federation of Bar Associations; Managing Director, Kanto Federation of Bar Associations Jun 2018 Audit & Supervisory Board Member of the Company Jun 2019 Outside Director, Japan Housing Inspection and Warranty Organization Co., Ltd. (current) Oct 2020 Opened Ito & Wasewa Law Office (current) Jun 2025 Director (Audit and Supervisory Committee Member) of the Company (current)
1960-04-20
Hiroshi KIZAKI
Director (Audit and Supervisory Committee Member)
Apr 1981 Joined Mitsubishi Corporation Oct 2000 President, Mitsubishi Corporation Finance PLC Apr 2004 Assistant to Corporate Executive Officer (Human Resources), Mitsubishi Corporation Jul 2008 Chief Financial Officer and Senior Vice President, Corporate Staff Functions, Mitsubishi Corporation Americas Apr 2011 General Manager, Integrated IT Planning Division, Mitsubishi Corporation Apr 2012 General Manager, Management Department, Global Environment and Infrastructure Business Group, Mitsubishi Corporation Jun 2015 Full-time Audit & Supervisory Board Member, Mitsubishi Corporation Jun 2019 Full-time Audit & Supervisory Board Member, Mitsubishi Foods Co., Ltd. Mar 2023 Outside Director, Outsourcing Inc. Jun 2023 Audit & Supervisory Board Member of the Company Jun 2025 Director (Audit and Supervisory Committee Member) of the Company (current)
1959-02-02
Sachiko IIZUKA
Director (Audit and Supervisory Committee Member)
Oct 1994 Joined Ohara School of Accounting (Ohara Gakuen) Jan 2000 Joined Diva Inc. (currently Avant Inc.) Mar 2012 Representative Director, Laurea Inc. (current) Jun 2019 Outside Audit & Supervisory Board Member, Kourakuen Holdings Corporation Sep 2019 Outside Audit & Supervisory Board Member, BeeX Inc. (current) Jun 2020 Outside Audit & Supervisory Board Member, NetOne Systems Co., Ltd. Mar 2021 Representative Partner, Cenxus Audit Corporation (current) Jun 2022 Outside Director (Audit and Supervisory Committee Member), NetOne Systems Co., Ltd. Jun 2025 Director (Audit and Supervisory Committee Member) of the Company (current)
1969-09-16
Large Shareholding Reports
Silchester International Investors LLP
2026-06-05
12.11%→13.17%
Silchester International Investors LLP
2025-11-04
11.10%→12.11%
Silchester International Investors LLP
2025-03-21
10.31%→11.10%
Silchester International Investors LLP
2023-11-15
11.33%→10.31%
Silchester International Investors LLP
2023-09-15
12.34%→11.33%
Silchester International Investors LLP
2023-03-02
11.32%→12.34%
Silchester International Investors LLP
2022-07-19
9.23%→11.32%
Disclosures
No disclosures
Primary Source Filings
TDnet
2026-08-05
Q1 Earnings Flash
FY ending Mar 2027
EDINET
2026-06-23
Annual Securities Report
Period: Apr 2025 – Mar 2026
EDINET
2026-06-05
Large Shareholding Report
TDnet
2026-02-10
Q3 Earnings Flash
FY ending Mar 2026
EDINET
2025-11-11
Semi-Annual Securities Report
Period: Apr 2025 – Sep 2025
EDINET
2025-11-04
Large Shareholding Report
TDnet
2025-08-06
Q1 Earnings Flash
FY ending Mar 2026
EDINET
2025-06-24
Annual Securities Report
Period: Apr 2024 – Mar 2025
EDINET
2025-03-21
Large Shareholding Report
TDnet
2025-02-10
Q3 Earnings Flash
FY ending Mar 2025
EDINET
2024-11-12
Semi-Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2024-08-05
Q1 Earnings Flash
FY ending Mar 2025
EDINET
2024-06-26
Annual Securities Report
Period: Apr 2023 – Mar 2024
EDINET
2024-02-14
Quarterly Securities Report
Period: Oct 2023 – Dec 2023
EDINET
2023-11-15
Large Shareholding Report
EDINET
2023-11-10
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-09-15
Large Shareholding Report
EDINET
2023-08-10
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
EDINET
2023-06-27
Annual Securities Report
Period: Apr 2022 – Mar 2023
EDINET
2023-03-02
Large Shareholding Report
EDINET
2023-02-14
Quarterly Securities Report
Period: Oct 2022 – Dec 2022
EDINET
2022-11-14
Quarterly Securities Report
EDINET
2022-08-12
Quarterly Securities Report
EDINET
2022-07-19
Large Shareholding Report
EDINET
2022-06-28
Annual Securities Report
EDINET
2022-02-14
Quarterly Securities Report
EDINET
2021-11-12
Quarterly Securities Report
EDINET
2021-08-13
Quarterly Securities Report
EDINET
2021-06-25
Annual Securities Report
EDINET
2021-02-12
Quarterly Securities Report
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →